title: Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma.
abstract: OBJECTIVE
  To determine the response, toxicity, and survival for children with progressive or recurrent medulloblastoma and germinoma using a single myeloablative course of chemotherapy supported by autologous hematopoietic stem cells.
  
  
  METHODS
  Subjects were in second remission or had minimal residual disease at the time of study entry. The conditioning regimen consisted of cyclophosphamide 6,000 mg/m(2) plus melphalan 180 mg/m(2).
  
  
  RESULTS
  Twenty-nine evaluable pediatric patients were accrued. The most frequent major toxicities were myelosuppression, infections, and stomatitis, but no toxic deaths were recorded. Best responses were: CR = 6, CCR = 13, PR = 6, SD = 2, and PD = 2. There were 6 medulloblastoma and 3 germinoma survivors with a median follow-up of 7.5 years (range = 2.8-10). Two germinoma survivors received radiotherapy after autografting for presumptive progressive disease.
  
  
  CONCLUSIONS
  Myeloablative chemotherapy consisting of cyclophosphamide and melphalan was tolerable in the relapsed brain tumor setting with 19/29 cases achieving CR or CCR status and 9/29 becoming long-term survivors.
authors.affiliation: Rady Children's Hospital, San Diego, California, USA. rkadota@chsd.org
authors.forename: Richard P
authors.initials: RP
authors.lastname: Kadota
authors.forename: Donald H
authors.initials: DH
authors.lastname: Mahoney
authors.forename: John
authors.initials: J
authors.lastname: Doyle
authors.forename: Reggie
authors.initials: R
authors.lastname: Duerst
authors.forename: Henry
authors.initials: H
authors.lastname: Friedman
authors.forename: Emi
authors.initials: E
authors.lastname: Holmes
authors.forename: Larry
authors.initials: L
authors.lastname: Kun
authors.forename: Tianni
authors.initials: T
authors.lastname: Zhou
authors.forename: Ian F
authors.initials: IF
authors.lastname: Pollack
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018237:Germinoma / Q000188:drug therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D008527:Medulloblastoma / Q000188:drug therapy* / Q000401:mortality; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D014182:Transplantation, Autologous
chemical_list: D003520:Cyclophosphamide; D008558:Melphalan